{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:15:26Z","timestamp":1783163726908,"version":"3.54.6"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cientifico e Tecnologico","doi-asserted-by":"publisher","award":["09\/2022"],"award-info":[{"award-number":["09\/2022"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008128","name":"Funda\u00e7\u00e3o Universidade do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["20\/2024"],"award-info":[{"award-number":["20\/2024"]}],"id":[{"id":"10.13039\/501100008128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejphar.2026.178993","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:45:29Z","timestamp":1779173129000},"page":"178993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review"],"prefix":"10.1016","volume":"1027","author":[{"given":"Melissa Talita","family":"Wiprich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuesllen Dondossola","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamy","family":"Colonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas de Oliveira","family":"Pacagnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Gomes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Redivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Lodetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Thereza","family":"Endler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Denise","family":"Bonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas da","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Pacheco","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178993_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.108080","article-title":"Prevalence, characteristics, and clinical outcomes of Huntington's disease in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"141","author":"Aderinto","year":"2025","journal-title":"Park. Relat. Disord."},{"issue":"103","key":"10.1016\/j.ejphar.2026.178993_bib2","article-title":"A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington's disease in adults","volume":"27","author":"Alharthi","year":"2024","journal-title":"Med (Balt)"},{"issue":"8","key":"10.1016\/j.ejphar.2026.178993_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-masked, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in huntington disease [RETIRED]: report of the guideline development subcommittee of the American academy of neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ejphar.2026.178993_bib5","first-page":"20","article-title":"The efficacy and safety of pridopidine on treatment of patients with huntington's disease: a systematic review and meta-analysis","volume":"29","author":"Asla","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and parkinson disease","volume":"221","author":"Bohnen","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1468-1331.2002.0354f.x","article-title":"Riluzole and olanzapine in huntington's disease","volume":"9","author":"Bonelli","year":"2002","journal-title":"Eur. J. Neurol."},{"issue":"24","key":"10.1016\/j.ejphar.2026.178993_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of huntington's disease: preliminary results comparing aripiprazole and tetrabenazine","volume":"15","author":"Brusa","year":"2009","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.ejphar.2026.178993_bib9","first-page":"317","article-title":"Corticostriatal dysfunction in huntington's disease: the basics","volume":"28","author":"Bunner","year":"2016","journal-title":"Front. Hum. Neurosci."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178993_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0028-3908(98)00081-1","article-title":"Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons","volume":"37","author":"Centonze","year":"1998","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1073858420972662","article-title":"Synaptic dysfunction in huntington's disease: lessons from genetic animal models","volume":"28","author":"Cepeda","year":"2022","journal-title":"Neuroscientist"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178993_bib12","article-title":"Pridopidine for the improvement of motor function in patients with Huntington's Disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chen","year":"2021","journal-title":"Front. Neurol."},{"issue":"67","key":"10.1016\/j.ejphar.2026.178993_bib13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"10","author":"Cubo","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","article-title":"Two years' follow-up of rivastigmine treatment in Huntington's disease","volume":"30","author":"de Tommaso","year":"2007","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178993_bib16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington's disease","volume":"19","author":"de Tommaso","year":"2004","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178993_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178993_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.21896","article-title":"Role of attentional resources on gait performance in Huntington's disease","volume":"23","author":"Delval","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2026.178993_bib18","article-title":"Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study","volume":"2","author":"Fekete","year":"2012","journal-title":"Tremor. Other. Hyperkinet. Mov. (N Y)."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington's disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40120-012-0005-7","article-title":"Effect of tetrabenazine on motor function in patients with huntington disease","volume":"29","author":"Ferrara","year":"2012","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.ejphar.2026.178993_bib21","first-page":"201","article-title":"Efficacy and safety of VMAT-2 inhibitors and dopamine stabilizers for Huntington's chorea: a systematic review, Meta-Analysis, and trial sequential analysis","volume":"22","author":"Floridia Rietmann","year":"2025","journal-title":"Med. Sci."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178993_bib23","first-page":"62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study","volume":"18","author":"Frank","year":"2009","journal-title":"Huntington Study Group\/TETRA-HD Investigators. BMC. Neurol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington disease","volume":"31","author":"Frank","year":"2008","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-024-01139-3","article-title":"Safety and efficacy of deutetrabenazine at high versus lower daily dosages in the ARC-HD Study to treat Chorea in Huntington disease","volume":"39","author":"Frank","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2026.178993_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gaitpost.2016.07.014","article-title":"Motor-cognitive dual-task deficits in individuals with early-mid stage Huntington disease","volume":"49","author":"Fritz","year":"2016","journal-title":"Gait Posture"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Furr Stimming","year":"2023","journal-title":"Lancet Neurol."},{"issue":"23","key":"10.1016\/j.ejphar.2026.178993_bib28","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/ijms23116089","article-title":"A new perspective on Huntington's Disease: how a neurological disorder influences the peripheral tissues","volume":"29","author":"G\u00f3mez-Jaramillo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11033-025-10852-1","article-title":"Evidence based molecular pathways, available drug targets, pre- clinical animal models and future disease modifying treatments of Huntington'S disease","volume":"52","author":"Goel","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178993_bib29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00702-013-1002-4","article-title":"The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex","volume":"120","author":"Gronier","year":"2013","journal-title":"J. Neural Transm."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178993_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biomedicines10061432","article-title":"Molecular pathophysiological mechanisms in Huntington's disease","volume":"10","author":"Jurcau","year":"2022","journal-title":"Biomedicines"},{"issue":"347","key":"10.1016\/j.ejphar.2026.178993_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jns.2014.09.053","article-title":"Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease","volume":"15","author":"Kegelmeyer","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10717544.2017.1413446","article-title":"The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis","volume":"25","author":"Liu","year":"2018","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178993_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JHD-190393","article-title":"Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease","volume":"9","author":"McGarry","year":"2020","journal-title":"J. Huntingtons. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JHD-190393","article-title":"Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease","volume":"9","author":"McGarry","year":"2020","journal-title":"J. Huntingtons. Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib43","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178993_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mdc3.12617","article-title":"Rating scales and performance-based measures for assessment of functional ability in Huntington's disease: Critique and recommendations","volume":"5","author":"Mestre","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.ejphar.2026.178993_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2020.09.011","article-title":"Prevalence of Huntington's disease in Southern sardinia, Italy","volume":"80","author":"Muroni","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178993_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","article-title":"A pilot study of the clinical efficacy and safety of memantine for Huntington's disease","volume":"13","author":"Ondo","year":"2007","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2026.178993_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178993_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1021\/acs.biochem.4c00811","article-title":"The huntingtin transport complex","volume":"64","author":"Prowse","year":"2025","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2026.178993_bib50","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: a systematic review","volume":"12","author":"Rodrigues","year":"2025","journal-title":"J. Huntingtons. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington's disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","article-title":"Rivastigmine in the treatment of Huntington's disease","volume":"9","author":"Rot","year":"2002","journal-title":"Eur. J. Neurol."},{"issue":"Pt A","key":"10.1016\/j.ejphar.2026.178993_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178993_bib54","first-page":"239","article-title":"Cognitive function in early clinical phase huntington disease after rivastigmine treatment","volume":"26","author":"Se\u0161ok","year":"2014","journal-title":"Psychiatr. Danub."},{"issue":"10","key":"10.1016\/j.ejphar.2026.178993_bib55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington's disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/13696998.2022.2033493","article-title":"Epidemiology and economic burden of Huntington's disease: a Canadian provincial public health system perspective","volume":"25","author":"Shaw","year":"2022","journal-title":"J. Med. Econ."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178993_bib57","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib58","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"issue":"272","key":"10.1016\/j.ejphar.2026.178993_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00415-025-13255-1","article-title":"Variation in the reported prevalence of Huntington's disease: a systematic review and guide to interpretation","volume":"24","author":"Thompson","year":"2025","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178993_bib60","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3390\/ijms25073845","article-title":"Huntington's Disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178993_bib61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00415-024-12771-w","article-title":"Total functioning capacity scale in Huntington's disease: natural course over time","volume":"272","author":"van der Zwaan","year":"2025","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178993_bib62","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1007\/s00415-022-11551-8","article-title":"Quality of life, health-related quality of life, and associated factors in Huntington's disease: a systematic review","volume":"270","author":"van Lonkhuizen","year":"2023","journal-title":"J. Neurol."},{"issue":"59","key":"10.1016\/j.ejphar.2026.178993_bib63","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"10","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ejphar.2026.178993_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241276489","article-title":"Efficacy and safety of riluzole for treating motor function in rare dyskinesia syndromes: a systematic review with meta-analysis","volume":"52","author":"Wang","year":"2024","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178993_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170267","article-title":"Pridopidine: overview of pharmacology and rationale for its use in Huntington's disease","volume":"7","author":"Waters","year":"2018","journal-title":"J. Huntingtons. Dis."},{"issue":"Pt 4","key":"10.1016\/j.ejphar.2026.178993_bib66","article-title":"Inhibiting cytosine-adenine-guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease","volume":"242","author":"Winquist","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178993_bib67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:16:34Z","timestamp":1783160194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926004759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"alternative-id":["S0014299926004759"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178993","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178993"}}